Australia's most trusted
source of pharma news
Tuesday, 22 October 2024
Posted 12 February 2024 AM
The TGA has approved a granule formulation of Vertex's Trikafta for children with cystic fibrosis (CF) as young as two years who have at least one F508del mutation in the CFTR gene.
The top-selling PBS listed drug was previously approved in tablet form for use in people with CF six years and older who have at least one F508del mutation in the CFTR gene.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.